News Conference News ESC 2023 IV Iron in HF Misses (Again) in HEART-FID, but Meta-analysis Sees a Role Shelley Wood August 26, 2023
News Conference News ESC Heart Failure 2023 Loop Diuretics Are Heavily Prescribed Outside of HF: That’s a Problem Shelley Wood May 23, 2023
News Conference News ESC Heart Failure 2023 More ARNI Insights Fortify Role in ‘Below Normal’ LVEF: PARAGLIDE-HF Shelley Wood May 22, 2023
News Conference News ACC 2023 IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF L.A. McKeown March 14, 2023
News Daily News HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act L.A. McKeown January 13, 2023
News Conference News HFSA 2022 New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented Todd Neale October 07, 2022
News Conference News ESC 2022 DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum Todd Neale August 27, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for July 2022 Todd Neale August 01, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for June 2022 Caitlin E. Cox July 04, 2022
News Conference News ESC Heart Failure 2022 HF Triple Therapy Doesn’t Seem Effective in True Preserved HF Shelley Wood May 25, 2022
News Conference News ACC 2022 QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis L.A. McKeown April 07, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report Michael O'Riordan January 27, 2022
News Daily News Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF L.A. McKeown December 07, 2021
News Daily News As Amyloidosis Field Explodes, Physicians Need to Spot and Treat Todd Neale October 20, 2021